BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2016 9:23:00 AM | Browse: 1696 | Download: 2634
 |
Received |
|
2015-10-16 08:17 |
|
Peer-Review Started |
|
2015-10-16 15:11 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2015-11-25 08:49 |
|
Revised |
|
2015-11-27 15:26 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2015-12-29 11:31 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2016-01-07 17:05 |
|
Articles in Press |
|
2016-01-07 17:05 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-01-11 13:39 |
|
Publish the Manuscript Online |
|
2016-01-21 09:23 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Sofosbuvir treatment and hepatitis C virus infection
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Masato Nakamura, Tatsuo Kanda, Yuki Haga, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Shin Yasui, Makoto Arai, Fumio Imazeki and Osamu Yokosuka |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
|
| Key Words |
Hepatitis C virus; Interferon; Interferon-free; Genotype; Sofosbuvir |
| Core Tip |
Sofosbuvir, a nucleotide-based NS5B inhibitor, is an effective treatment against pangenotypic strains of hepatitis C virus (HCV). Sofosbuvir-containing regimens have attained extremely high rates of sustained virologic response. Because regimens including sofosbuvir result in fewer adverse events than interferon-based regimens, sofosbuvir has taken a central role in HCV treatment.
|
| Publish Date |
2016-01-21 09:23 |
| Citation |
Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190
|
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i3/183.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i3.183 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
